Incannex Healthcare Ltd ADR (IXHL) - Total Liabilities
Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) has total liabilities worth $5.05 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Incannex Healthcare Ltd ADR - Total Liabilities Trend (2006–2025)
This chart illustrates how Incannex Healthcare Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. See IXHL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Incannex Healthcare Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Incannex Healthcare Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gyeongnam Steel Co. Ltd
KQ:039240
|
Korea | ₩45.20 Billion |
|
Siyata Mobile Inc
NASDAQ:SYTA
|
USA | $3.24 Million |
|
AlphaTime Acquisition Corp Ordinary Shares
NASDAQ:ATMC
|
USA | $7.78 Million |
|
Nuenergy Gas Ltd
AU:NGY
|
Australia | AU$17.10 Million |
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
USA | $324.88 Million |
|
Metalstech Ltd
AU:MTC
|
Australia | AU$2.86 Million |
|
Dividend Select 15 Corp
TO:DS
|
Canada | CA$503.98K |
|
Sarine Technologies Ltd
TA:SARN
|
Israel | ILA11.68 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Incannex Healthcare Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Incannex Healthcare Ltd ADR.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 41.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Incannex Healthcare Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Incannex Healthcare Ltd ADR (2006–2025)
The table below shows the annual total liabilities of Incannex Healthcare Ltd ADR from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $7.06 Million | +21.06% |
| 2024-06-30 | $5.83 Million | +30.95% |
| 2023-06-30 | $4.45 Million | +120.66% |
| 2022-06-30 | $2.02 Million | +255.66% |
| 2021-06-30 | $567.30K | -22.96% |
| 2020-06-30 | $736.35K | -21.58% |
| 2019-06-30 | $938.95K | -14.39% |
| 2018-06-30 | $1.10 Million | -6.52% |
| 2017-06-30 | $1.17 Million | +12.24% |
| 2016-06-30 | $1.05 Million | -82.04% |
| 2015-06-30 | $5.82 Million | -3.56% |
| 2014-06-30 | $6.03 Million | +7.10% |
| 2013-06-30 | $5.63 Million | +41.39% |
| 2012-06-30 | $3.98 Million | -18.16% |
| 2011-06-30 | $4.87 Million | +29.30% |
| 2010-06-30 | $3.77 Million | -54.27% |
| 2009-06-30 | $8.23 Million | +667.12% |
| 2008-06-30 | $1.07 Million | +519.54% |
| 2007-06-30 | $173.25K | -49.50% |
| 2006-06-30 | $343.08K | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more